このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Reliability of Expired Allergens in Patch Testing: A Comparative Study With Non-Expired Series

2026年8月10日 更新者:Laurie Parsons、University of Calgary
Patch testing remains the gold standard in the diagnosis of allergic contact dermatitis. Patches used in testing consist of a wide spectrum of allergens, with variability in the stability of products over time. Due to limited allergen stability, careful storage and preparation is needed to prevent product degradation over time. Expiration dates are provided by manufacturers to ensure stability and reactivity, while minimizing the risk of product degradation contributing to inaccurate testing results. Preparation of patch series can be time intensive and procurement of allergens comes with an associated economic burden. Expired allergens are not routinely used in patch testing, however many clinics have expired allergens accessible. There is paucity of evidence comparing the reactivity of expired vs non-expired patch series. If expired allergens remain effective, this could result in significant cost-savings and accessibility implications for dermatology practice.

調査の概要

詳細な説明

In brief, review of the medical literature showed two comparable studies out of India and Spain suggesting that expired allergen series may be used beyond their labeled expiry dates, with some variability noted amongst duration of expiry, that the investigators will also aim to analyze.

Regarding allergen stability, there were also several studies focused on this domain. The European Society of Contact Dermatitis (ESCD) released guidelines in 2015, outlining optimal methods for allergen storage such as storage at 4 degrees celsius and strict protection from ultraviolet light exposure. While most allergens are dispersed in petrolatum (white soft paraffin), some substances are better tested in solutions such as water (aqueous) or ethanol. Several allergens with high vapour pressure require more frequent renewal and strict storage conditions such as fragrance chemicals, acrylates and isocyanates. Other substances such as glutaraldehyde in petrolatum (pet.) and formaldehyde in aqueous solution (aq.) are susceptible to instability and deterioration. An additional study assessed volatility over time of several select compounds and described high volatility in acrylates, glutaraldehyde, and fragrances, while describing partial volatility of formaldehyde and low volatility of nickel sulfate.

Study participants will include all eligible adults seen in patch testing clinic who maintain an indication for patch testing and consent to participation. The study will be utilizing 10 allergens from the North American Contact Dermatitis Group (NACDG) 80 Series for inclusion in the study.

The allergen selections are primarily based on compounds with a higher likelihood for volatility, in addition to inclusion of two comparator compounds with lower volatility. Expiration intervals include 1 year, 2 years, 3 years, and 4 years. The compounds selected are as follows, including their dispersion compound: nickel sulfate hexahydrate (5% pet.), cobalt (II) chloride hexahydrate (2.5% pet.), hydroperoxides of linalool (1% pet.), hydroperoxides of limonene (0.3% pet.), fragrance mix 1 (8.0% pet.), myroxylon pereirae resin (balsam of Peru) (25.0% pet.), methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) (0.02% aq.), formaldehyde (2.0% aq.), tixocortol-21-pivalate (1.0% pet.), and budesonide (0.1% pet.).

The patch testing results will be compared to corresponding non-expired allergens from the same manufacturer with the same preparation tested simultaneously. Both series will be placed simultaneously in differing locations on the participant's back, ensuring both are placed in sun protected areas with no underlying dermatitis.

Once in clinic, standard patch test series are applied on patch testing day, with the participant instructed not to shower or scratch the area throughout testing. At 48h, the patches are removed and photos are taken of the participant's back which are sent to the Dermatologist for virtual reading. At either 96h or 120h, the participant returns to the clinic for final reading. Both morphology and intensity of positives are graded on a standard patch test scale (irritant reaction), +/- for doubtful, + for erythema and infiltration, ++ for edematous or vesicular and +++ for spreading, bullous or ulcerative. Positive allergens scored + or greater are considered a true allergic contact allergen and assessed for relevance based on clinical context. The Dermatologist provides information sheets on all positive allergens, counsels on the relevance to their clinical history and allergen avoidance going forward, as well as providing the participant with a safe product list via the ACDS Contact Allergen Management Program (CAMP) database.

The investigators are aiming for enrolment of 100 participants which should theoretically provide the study with at least 5-10 participants testing positive to each of the four listed allergens with higher volatility and 20+ participants testing positive to the allergens with lower volatility. The investigators are aiming to assess concordance between expired and non-expired allergen reactions (positive vs negative), in addition to agreement in reaction intensity, differences in morphology, rates of false positives/negatives compared to control and concordance of irritant reaction between interventions.

The study will serve to lend valuable evidence as to whether expired allergens maintain clinical utility and could serve to reduce product waste, lower the economic burden and further improve accessibility of patch testing for use in resource limited settings.

研究の種類

介入

入学 (推定)

100

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Alberta
      • Calgary、Alberta、カナダ、T2T 5C7
        • Richmond Road Diagnostic Treatment Centre
        • コンタクト:
        • 主任研究者:
          • Laurie Parsons, Medical Doctor

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Adults (age 18 years or older) referred for patch testing.

Exclusion Criteria:

  • Relative or absolute contraindication to patch testing
  • Wide spread dermatitis prior to patch placement
  • Inability to return to clinic for reading of results
  • Patient non-consenting

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:診断
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
他の:Enrolled Study Participants
All enrolled participants will be simultaneously patch tested with both expired and non-expired patches. Therefore, there is no difference in intervention amongst study participants.
All enrolled participants will be simultaneously patch tested with both expired and non-expired patches. Therefore, there is no difference in intervention amongst study participants.
All enrolled participants will be simultaneously patch tested with both expired and non-expired patches. Therefore, there is no difference in intervention amongst study participants.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Patch Testing Response (Positive/Negative) Concordance Rate (%) Between Non-Expired and Expired Allergens
時間枠:Standard patch test series are applied on Day 0. Participant removal of patches on Day 2 and self photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores.
Each allergen will be graded on response using a standard patch test scale including: irritant reaction ['IR'], '+/-' for doubtful, '+' for erythema and infiltration, '++' for edematous or vesicular and '+++' for spreading, bullous or ulcerative response that will be graded by the participating Dermatologist. Reactions graded '+', "++", or "+++" are consider a positive result. Concordance rate will be expressed as a percentage (%) between tested allergens that were non-expired and that were expired (i.e. Nickel sulfate hexahydrate was found to have a 92% concordance rate, meaning that in 92% of cases, the Nickel allergen in the non-expired and expired patches were both found to both be either positive or negative while in 8% of cases the response differed per the scale listed above.)
Standard patch test series are applied on Day 0. Participant removal of patches on Day 2 and self photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores.

二次結果の測定

結果測定
メジャーの説明
時間枠
Reaction/Morphology Scoring Concordance (%)
時間枠:Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
For each positive allergen, severity (i.e. '+/-', '+', '++', "+++") and morphology (i.e. erythema, infiltration, edematous, vesicular, bullous, ulcerated) will be recorded. Concordance rate will be expressed as a percentage (%) between tested allergens that were non-expired and that were expired (i.e. Nickel sulfate hexahydrate was found to have a 92% concordance rate, meaning that in 70% of cases, the Nickel allergen in the non-expired and expired patches were both found to have the exact same severity and morphology, while in 30% of cases the severity and/or morphology differed per the scale listed above.)
Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
Stability Concordance (%) Amongst Mediums
時間枠:Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
Each allergen is suspended within a medium, either petrolatum or aqueous solution. Not only will concordance (%) of positive and negative reactions be assessed amongst allergens and compared between non-expired and expired, but also between mediums to determine if there is a difference in stability over time amongst mediums used to determine if particular mediums result in degradation over time.
Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
Irritant Reaction Rates (%)
時間枠:Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
Final patch reading will score reactions on a standarized scale, with irritant reaction representing a negative reaction. However, we will compare rates and concordance (%) of irritant reactions between allergens to determine if their is reproducibility, or if expired allergens result in differing rates of irritant reactions. (i.e. Nickel sulfate allergen was shown to have a 50% increased rate of irritant reactions between the expired to non-expired allergens, meaning that Nickel resulted in an irritant reaction in 6 cases of the expired Nickel and 4 cases of the non-expired Nickel, suggesting that expired Nickel allergens may become more irritating over time, resulting in more irritant reactions.
Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Laurie Parsons, Medical Doctor、University Of Calgary

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年9月1日

一次修了 (推定)

2027年12月1日

研究の完了 (推定)

2027年12月1日

試験登録日

最初に提出

2026年7月7日

QC基準を満たした最初の提出物

2026年8月10日

最初の投稿 (実際)

2026年8月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年8月14日

QC基準を満たした最後の更新が送信されました

2026年8月10日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Aside from eventual publication of study results to help guide practice, we will not be sharing granular study data with other researchers for expansion of the study.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する